<DOC>
	<DOCNO>NCT00996853</DOCNO>
	<brief_summary>The focus study assess safety GSK 's H1N1 vaccine real life condition soon vaccine use , mass vaccination programme , system rapid generation , communication evaluation safety data . This study commitment European Medicines Agency ( EMEA ) , part GlaxoSmithKline Biologicals ' ( GSK Biologicals ' ) risk management plan pandemic influenza vaccination .</brief_summary>
	<brief_title>Post-Authorization Safety Study GSK Biologicals ' Pandemic Influenza Vaccine ( H1N1 ) United Kingdom</brief_title>
	<detailed_description>Collaborator : Medicines Healthcare product Regulatory Agency</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Written inform consent , assent appropriate , obtain subject/from subject 's parent ( ) / Legally Acceptable Representative ( ) ( LAR ) . A male female subject vaccinate first dose GSK Biologicals ' H1N1 pandemic influenza vaccine shortly ( &lt; 24h ) recruit study , within GP practice participate study subject register . Subjects Investigator believe and/or parent ( ) /LAR comply requirement protocol Subjects already vaccinate H1N1 pandemic vaccine study enrolment . Child care</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>safety</keyword>
	<keyword>Influenza</keyword>
	<keyword>vaccine</keyword>
	<keyword>reactogenicity</keyword>
	<keyword>swine flu</keyword>
</DOC>